We founded SmartGenRx Pty Ltd, a Sydney-based social venture between The George Institute for Global Health and Bupa Australia, focused on developing innovative pharmaceutical products to address critical health problems.
Trials by The George Institute have consistently shown that combination pills reduce both blood pressure and cholesterol, to levels that could halve the risk of having a heart attack or stroke.
Our research has shown that patients who have suffered a stroke or heart attack are 40 per cent more likely to stick to their treatments if they take just one combination pill – instead of four different tablets each day.
SmartGenRx is currently developing a new combination pill - k a ‘polypill’ and undertaking regulatory trials with a view to introducing this to the market in Australia in the next few years. By increasing the likelihood that people will take their medication consistently, we can reduce the devastating effect of heart disease in Australia and around the world.